TITLE

Towards an effective malaria vaccine

AUTHOR(S)
Aide, Pedro; Bassat, Quique; Alonso, Pedro L.
PUB. DATE
June 2007
SOURCE
Archives of Disease in Childhood;Jun2007, Vol. 92 Issue 6, p476
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses developments in the area of malaria vaccine. It discusses whether malaria vaccine is necessary, why a malaria vaccine is not available yet, whether a malaria vaccine is feasible, strategies for vaccine design, including vaccines designed according to the target population and vaccines designed according to the life cycle stage targeted, and vaccines in clinical trials.
ACCESSION #
25471885

 

Related Articles

  • As Trials Advance for a Malaria Vaccine, Policy Makers Urged to Plan for Its Use. Voelker, Rebecca // JAMA: Journal of the American Medical Association;12/1/2010, Vol. 304 Issue 21, p2348 

    The article reports that the clinical trials for a malaria vaccine in sub-Saharan Africa is on its third phase. In 2001, the nonprofit PATH Malaria Vaccine Initiative (MVI) and the vaccine's developer GlaxoSmithKline Biologicals partnered to develop the vaccine for infants and young children in...

  • Vaccines for malaria -- prospects and promise. Chaun, V. S. // Current Science (00113891);6/10/2007, Vol. 92 Issue 11, p1525 

    Malaria has remained a major global health problem and despite serious efforts for many years, a successful malaria vaccine has remained elusive. Main reasons among many are highly complex life cycle of the parasite, extensive polymorphism of key malaria proteins and lack of correlates for...

  • Quarter-century quest for malaria vaccine shows signs of success. Opar, Alisa // Nature Reviews Drug Discovery;Dec2011, Vol. 10 Issue 12, p887 

    The article reports that GlaxoSmithKline (GSK) led ongoing trial of the vaccine candidate RTS,S, provides children with nearly 50% protection from severe bouts of the disease. The large-scale trial enrolled over 15,000 children aged either 6-12 weeks or 5-17 months in seven countries in...

  • Hopes rise for malaria vaccine.  // National Catholic Reporter;11/27/2009, Vol. 46 Issue 3, p4 

    The article reports on the production of RTSS, a malaria vaccine, by researchers in Africa. The vaccine is being developed by GlaxoSmithKline Biologicals SA and the clinical trials are expected to start soon. The Catholic Information Service for Africa has reported that scientists are on the...

  • Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications. Gandhi, Kavita; Thera, Mahamadou A.; Coulibaly, Drissa; Traoré, Karim; Guindo, Ando B.; Ouattara, Amed; Takala-Harrison, Shannon; Berry, Andrea A.; Doumbo, Ogobara K.; Plowe, Christopher V. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    The malaria vaccine candidate RTS,S/AS01 is based on immunogenic regions of Plasmodium falciparum circumsporozoite protein (CSP) from the 3D7 reference strain and has shown modest efficacy against clinical disease in African children. It remains unclear what aspect(s) of the immune response...

  • Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. Thompson, Fiona M.; Porter, David W.; Okitsu, Shinji L.; Westerfeld, Nicole; Vogel, Denise; Todryk, Stephen; Poulton, Ian; Correa, Simon; Hutchings, Claire; Berthoud, Tamara; Dunachie, Susanna; Andrews, Laura; Williams, Jack L.; Sinden, Robert; Gilbert, Sarah C.; Pluschke, Gerd; Zurbriggen, Rinaldo; Hill, Adrian V. S. // PLoS ONE;2008, Vol. 3 Issue 1, p1 

    Background. Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely to provide the most effective malaria vaccine. This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune...

  • Malaria vaccine protected against parasites similar to vaccine strain.  // Infectious Disease News;Oct2011, Vol. 24 Issue 10, p45 

    The article discusses research which revealed that malaria vaccine prevents clinical malaria caused by parasites that were similar to the vaccine strain, referencing a study by M. A. Thera published in a 2011 issue of the "New England Medical Journal."

  • Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission. Brooks, Alan; Bri�t, Olivier J. T.; Hardy, Diggory; Steketee, Richard; Smith, Thomas A. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Introduction: The RTS,S/AS01 pre-erythrocytic malaria vaccine is in phase III clinical trials. It is critical to anticipate where and how it should be implemented if trials are successful. Such planning may be complicated by changing levels of malaria transmission. Methods/results: Computer...

  • Vaccine combos are best hope for beating malaria. Coghlan, Andy // New Scientist;10/23/2004, Vol. 184 Issue 2470, p7 

    The article reports that researchers have finally produced a malaria vaccine that could save many lives, even though it is only partly effective. The experimental vaccine, known only as RTS, S/AS02A targets Plasmodium falciparum, the most dangerous malaria parasite. The results so far are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics